AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Instagram Outage Disrupts Thousands of U.S. Users 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Dublin, Aug. 11, 2017 -- The "Seasonal Influenza Vaccines" report has been added to Research and Markets' offering.
Seasonal influenza is an acute viral infection that is spread by person-to-person transmission. Influenza, commonly referred to as the flu, circulates worldwide and can affect anyone in any age group, although annual epidemics peak during winter in temperate climates. Seasonal influenza can be type A, B, or C. Type A influenza viruses are considered to be the most virulent of the three types and can be further classified by serotype based on antibody response to the virus.
Seasonal influenza presents significant public health problems for nearly every country, largely because of the cost associated with the treatment or management of the disease, as well as the toll on the workforce. Vaccination against seasonal influenza is the most effective method of preventing influenza infection. However, global vaccination rates remain lower than the levels recommended by the World Health Organization.
Recent events and opinion:
- Quadrivalent vaccines are seeing rapid uptake and will gradually replace trivalent vaccines in all patient groups in the US and EU markets
- The broadening of recommendations to include school-aged children will drive EU market growth significantly
- Adjuvanted vaccines in development have the potential to address unmet needs in infants and the elderly
Key Topics Covered:
Forecast: Seasonal Influenza Vaccines
Executive Summary
- Market Overview and Trends
- Key Drivers and Resistors of Conversion to QIVs
- Market Definition
- US Market Forecast
- France Market Forecast
- Germany Market Forecast
- Italy Market Forecast
- Spain Market Forecast
- UK Market Forecast
Marketed Drugs: Seasonal Influenza Vaccines
- Executive Summary
- Product Overview
- Product profile: FluMist QIV
- Product profile: Flucelvax QIV
- Product profile: Fluzone High-Dose
Pipeline: Seasonal Influenza Vaccines
- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): Fluad QIV
For more information about this report visit https://www.researchandmarkets.com/research/gz6m4x/seasonal
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Vaccines
